The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid Leukemia
Open accessAbstract
BACKGROUND: Sensitization of leukemic cells with hematopoietic growth factors may enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). METHODS: In a multicenter randomized trial, we assigned patients (age range, 18 to 60 years) with newly diagnosed AML to receive cytarabine plus idarubicin (cycle 1) and cytarabine plus amsacrin (cycle 2) with granulocyte colony-stimulating factor (G-CSF) (321 patients) or without G-CSF (319). G-CSF was given concurrently with chemotherapy only. Idarubicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cytotoxicity of cytarabine in the context of G-CSF to have a greater effect. The effect of G-CSF on disease-free survival was assessed in all patients and in cytogenetically distinct prognostic subgroups. RESULTS: After induction chemotherapy, the rates of response were not significantly different in the two groups. After a median follow-up of 55 months, patients in complete remission after induction chemotherapy plus G-CSF had a higher rate of disease-free survival than patients who did not receive G-CSF (42 percent vs. 33 percent at four years, P=0.02), owing to a reduced probability of relapse (relative risk, 0.77; 95 percent confidence interval, 0.61 to 0.99; P=0.04). G-CSF did not significantly improve overall survival (P=0.16). Although G-CSF did not improve the outcome in the subgroup with an unfavorable prognosis, the 72 percent of patients with standard-risk AML benefited from G-CSF therapy (overall survival at four years, 45 percent, as compared with 35 percent in the group that did not receive G-CSF [relative risk of death, 0.75; 95 percent confidence interval, 0.59 to 0.95; P=0.02]; disease-free survival, 45 percent vs. 33 percent [relative risk, 0.70]; 95 percent confidence interval, 0.55 to 0.90; P=0.006). CONCLUSIONS: Sensitization of leukemic cells with growth factors is a clinically applicable means of enhancing the efficacy of chemotherapy in patients with AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]
Bishop, J., Matthews, J., Young, G., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M., & Fox, R. (1996) · Blood · doi:10.1182/blood.v87.5.1710.1710 · Cited by 458
Wheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M., Harrison, C. J., Rees, J. K. H., Stevens, R. F., & Walker, H. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01684.x · Cited by 434
Estey, E. H., Thall, P. F., Pierce, S., Cortes, J., Beran, M., Kantarjian, H., Keating, M. J., Andreeff, M., & Freireich, E. (1999) · Blood · doi:10.1182/blood.v93.8.2478 · Cited by 224
Hematopoietic growth factors and their receptors in acute leukemia
Lowenberg, B., & Touw, I. (1993) · Blood · doi:10.1182/blood.v81.2.281.281 · Cited by 210
Löwenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G. J., Verhoef, G. E. G., Vellenga, E., Wijermans, P., Berneman, Z. N., Dekker, A. W., Stryckmans, P. A., et al. (1997) · PubMed · doi:10.1182/blood.v90.8.2952 · Cited by 205
Self-citationOhno, R., Naoe, T., Kanamaru, A., Yoshida, M., Hiraoka, A., Kobayashi, T., Ueda, T., Minami, S., MORISHIMA, Y., & Saito, Y. (1994) · Blood · doi:10.1182/blood.v83.8.2086.2086 · Cited by 153
Estey, E. H., Thall, P., Kantarjian, H. M., O'Brien, S. M., Koller, C., Beran, M., Gutterman, J. U., Deisseroth, A. B., & Keating, M. J. (1992) · Blood · doi:10.1182/blood.v79.9.2246.2246 · Cited by 150
Witz, F., Sadoun, A., Perrin, M. C., Berthou, C., Brière, J., Cahn, J.-Y. Y., Lioure, B., Witz, B., François, S., Desablens, B., et al. (1998) · PubMed · doi:10.1182/blood.v91.8.2722.2722_2722_2730 · Cited by 146
Löwenberg, B., Boogaerts, M. A., Daenen, S. M. G. J., Verhoef, G. E. G., Hagenbeek, A., Vellenga, E., Ossenkoppele, G. J., Huijgens, P. C., Verdonck, L. F., der Lelie, J. V., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.12.3496 · Cited by 126
Self-citationZittoun, R., Suciu, S., Mandelli, F., de Witte, T., Thaler, J., Stryckmans, P. A., Hayat, M., Peetermans, M. E., Cadiou, M., Solbu, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2150 · Cited by 120
Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia
Schiffer, C. (1996) · Blood · doi:10.1182/blood.v88.10.3675.bloodjournal88103675 · Cited by 93
Reuter, C. W., der Landwehr, U. A., Schleyer, E., Zühlsdorf, M., Ameling, C., Rolf, C., Wormann, B. J., Büchner, T., & Hiddemann, W. (1994) · PubMed · Cited by 46
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
“inv(16): Inversion of a segment of chromosome 16 that produces the CBF b -MYH11 fusion.”
BackgroundMethodInfluentialSelf-citationEstey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
Metadata
- Authors
- Löwenberg, B., van Putten, W., Theobald, M., Gmür, J., Verdonck, L., Sonneveld, P., Fey, M., Schouten, H., de Greef, G., Ferrant, A., Kovacsovics, T., Gratwohl, A., Daenen, S., Huijgens, P., & Boogaerts, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-21
- Volume
- 349
- Issue
- 8
- Pages
- 743-752
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119626196
- Cited by
- 386
- References
- 15
- FWCI
- 11.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.